Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.
Daniel P. Petrylak, MD, professor of medicine and urology and co-leader of Cancer Signaling Networks with Yale Cancer Center, as well as a 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer (mHSPC).
The open-label, phase 3 ENZAMET trial randomized men with mHSPC to testosterone suppression plus enzalutamide (Xtandi) or a standard nonsteroidal antiandrogen. Results showed that enzalutamide was associated with significantly longer progression-free and overall survival (OS) compared with standard therapy in this patient population. Similar findings were demonstrated in the phase 3 LATITUDE and STAMPEDE trials, Petrylak says.
However, unlike the LATITUDE and STAMPEDE trials, ENZAMET allowed patients to received prior docetaxel. Although it is understood that docetaxel does not improve the OS benefit associated with enzalutamide, future research efforts must determine whether docetaxel is needed, Petrylak concludes.